Pub. Date : 2021
PMID : 34000725
1 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | mOS from 1st-line therapy with tyrosine kinase inhibitor plus sorafenib-regorafenib-lenvatinib was 29.5 months; that with lenvatinib-sorafenib-regorafenib was not obtained. | Sorafenib | Moloney sarcoma oncogene | Mus musculus |